Updated Data From the TRIMM-2 Trial of Talquetamab and Daratumumab in RRMM
Bhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.